The class explained
CJC-1295 Ipamorelin as a Growth Hormone Secretagogue
Not synthetic growth hormone — a pair of signals that prompt the pituitary to release its own, and what the secretagogue literature shows and withholds.
In plain English
A growth hormone secretagogue is any compound that makes the body release its own growth hormone (GH), rather than injecting GH from outside. CJC-1295 Ipamorelin is exactly that — a two-part secretagogue. The difference matters: injected GH overrides the body's controls and sits at a flat level, while a secretagogue nudges the pituitary gland to fire GH in its own natural pulses, with the body's feedback brakes still attached. CJC-1295 is the long-acting half (it copies the natural "go" signal, GHRH); ipamorelin is the selective half (it hits the separate ghrelin switch). Studies of each part show real rises in GH and IGF-1. But "secretagogue" describes how it works, not that it is safe or approved — neither piece is FDA-approved, and the combined product has never been through a human trial. This page explains the class and where its evidence runs out.
What 'secretagogue' means here
Secretagogue is simply "a thing that triggers secretion." In this case the secretion is growth hormone, and there are two natural triggers the body already uses: GHRH (growth-hormone-releasing hormone) and ghrelin, the hormone that also signals hunger. CJC-1295 is a long-acting copy of the GHRH trigger; ipamorelin is a synthetic copy of the ghrelin trigger, refined to release GH without the side actions of cruder versions. Because each trigger has its own receptor and its own internal pathway, hitting both at once produces a bigger combined GH pulse than either alone — the supra-additive effect documented at the receptor level [5] and in acute human studies [3]. That dual-trigger design is the entire reason a GHRH analogue and a GHRP are paired.
What the secretagogue evidence establishes
On the GHRH side, a single subcutaneous dose of CJC-1295 with DAC raised mean plasma GH two- to ten-fold for six or more days and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults, with IGF-1 above baseline up to 28 days after repeat dosing [1]; pulsatile GH release persisted during continuous stimulation, with trough GH up about 7.5-fold and mean GH and IGF-1 up 46% and 45% [7]. On the GHRP side, ipamorelin was the first selective secretagogue — full GH release with no rise in ACTH or cortisol even far above the GH-effective dose [2]. The class can also be read for body-composition effect through its best-studied GHRH analogue: a 2026 meta-analysis of tesamorelin found significant visceral-fat and hepatic-fat reduction and increased lean mass and IGF-1, without serious adverse events [8] — context for the secretagogue mechanism, not data on this blend.
What the secretagogue class does not resolve
The honest secretagogue picture includes its open questions. The best available safety synthesis found GH secretagogues generally well tolerated, but flagged the chief concern as increased blood glucose from decreased insulin sensitivity, and noted that long-term data on cancer incidence and mortality are still needed [6]. Raising GH and IGF-1 carries a theoretical oncologic concern because IGF-1 is anti-apoptotic and proliferative, and epidemiology links higher circulating IGF-1 with some cancers — though causality for secretagogue use is unestablished. For athletes, every compound in this class is WADA-prohibited at all times under Section S2. And none of it is approved: a growth hormone secretagogue like CJC-1295 Ipamorelin is, at present, a research chemical whose combined form has no controlled human trial behind it.